Neuren Pharmaceuticals Limited (NEU.AX)
Neuren Pharmaceuticals Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Hawthorn East, VIC, AU. The stock last traded at $23.57, up 1.12% on the session, giving a market capitalisation of $2.99B. Its beta of 1.62 implies it has historically moved more than the broad market.
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Neuren Pharmaceuticals Limited is most often compared with the following Healthcare names: